- Home
- MYGN vs MIRM Comparison
MYGN vs MIRM Comparison
Compare MYGN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYGN | MIRM |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.2M | 5.7B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MYGN | MIRM |
|---|---|---|
| Price | $4.65 | $98.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $7.64 | ★ $115.33 |
| AVG Volume (30 Days) | ★ 1.5M | 822.2K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | $19,138,000.00 |
| Revenue This Year | $6.89 | $26.22 |
| Revenue Next Year | $5.35 | $22.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $3.76 | $37.83 |
| 52 Week High | $8.59 | $109.28 |
Technical Indicators
Market Signals| Indicator | MYGN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 60.05 |
| Support Level | $4.23 | $97.49 |
| Resistance Level | $5.69 | $107.51 |
| Average True Range (ATR) | 0.25 | 3.66 |
| MACD | 0.04 | 1.16 |
| Stochastic Oscillator | 56.33 | 92.00 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.